380 related articles for article (PubMed ID: 28922433)
1. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
[TBL] [Abstract][Full Text] [Related]
2. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
3. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
4. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
[TBL] [Abstract][Full Text] [Related]
5. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
[TBL] [Abstract][Full Text] [Related]
6. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
De Francesco V; Pontone S; Bellesia A; Serviddio G; Panetta C; Palma R; Zullo A
Dig Liver Dis; 2018 Feb; 50(2):139-141. PubMed ID: 29089267
[TBL] [Abstract][Full Text] [Related]
7. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
8. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
9. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
10. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Lee JW; Kim N; Nam RH; Lee SM; Soo In C; Kim JM; Lee DH
J Gastroenterol Hepatol; 2019 Apr; 34(4):666-672. PubMed ID: 30726563
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
[TBL] [Abstract][Full Text] [Related]
14. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
[TBL] [Abstract][Full Text] [Related]
15. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
[TBL] [Abstract][Full Text] [Related]
16. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
[TBL] [Abstract][Full Text] [Related]
17. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
[TBL] [Abstract][Full Text] [Related]
18. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
Miehlke S; Frederking D; Günther T; Glocker E; Eisele B; Andresen V; Schröder S; Morgner A
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28833925
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
